BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30404612)

  • 41. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
    Machida N; Yoshino T; Boku N; Hironaka S; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Asaka M
    Jpn J Clin Oncol; 2008 Oct; 38(10):689-94. PubMed ID: 18845522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
    Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
    Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic Value of Carcinoembryonic Antigen (CEA), AFP, CA19-9 and CA125 for Patients with Colorectal Cancer with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy.
    Huo YR; Huang Y; Liauw W; Zhao J; Morris DL
    Anticancer Res; 2016 Mar; 36(3):1041-9. PubMed ID: 26976996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma.
    Osoegawa A; Kometani T; Fukuyama S; Hirai F; Seto T; Sugio K; Ichinose Y
    Ann Thorac Cardiovasc Surg; 2016; 22(1):6-11. PubMed ID: 26289631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen.
    He WZ; Rong YM; Jiang C; Liao FX; Yin CX; Guo GF; Qiu HJ; Zhang B; Xia LP
    Chin J Cancer; 2016 Jun; 35(1):58. PubMed ID: 27357402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
    Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
    Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of perioperative change of CEA level in colorectal patients when pre-operative level is normal.
    Lan YT; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC; Yang SH
    Hepatogastroenterology; 2012 May; 59(115):717-20. PubMed ID: 22024225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.
    Sunakawa Y; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Ichikawa W
    Target Oncol; 2017 Dec; 12(6):787-794. PubMed ID: 29064002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
    Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
    Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer.
    Kos J; Nielsen HJ; Krasovec M; Christensen IJ; Cimerman N; Stephens RW; Brünner N
    Clin Cancer Res; 1998 Jun; 4(6):1511-6. PubMed ID: 9626470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer.
    Ailawadhi S; Sunga A; Rajput A; Yang GY; Smith J; Fakih M
    Oncology; 2006; 70(1):49-53. PubMed ID: 16446549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study.
    Fiala O; Finek J; Buchler T; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Liska V; Topolcan O
    Target Oncol; 2015 Dec; 10(4):549-55. PubMed ID: 25875421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
    Knychalski B; Lukieńczuk T
    Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigation of Efficacy Evaluation Comparison of cfDNA and CEA in Colorectal Cancer.
    Yu D; An G; Xu L
    Clin Lab; 2016 Oct; 62(10):1947-1953. PubMed ID: 28164530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study.
    John SK; Robinson SM; Rehman S; Harrison B; Vallance A; French JJ; Jaques BC; Charnley RM; Manas DM; White SA
    Dig Surg; 2013; 30(4-6):293-301. PubMed ID: 23969407
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer].
    Uehara M; Manaka D; Baba S; Oji Y; Hirata K; Shimizu M; Noguchi M
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1413-7. PubMed ID: 17876139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.